Editas Medicine, Inc. Stock price

Equities

EDIT

US28106W1036

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
7.42 USD -0.27% Intraday chart for Editas Medicine, Inc. -5.24% -26.75%
Sales 2024 * 34.3M Sales 2025 * 24.82M Capitalization 591M
Net income 2024 * -206M Net income 2025 * -242M EV / Sales 2024 * 9.88 x
Net cash position 2024 * 252M Net cash position 2025 * 95M EV / Sales 2025 * 20 x
P/E ratio 2024 *
-3.02 x
P/E ratio 2025 *
-2.9 x
Employees 265
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.09%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Editas Medicine, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 02:05 PM
Barclays Adjusts Price Target on Editas Medicine to $11 From $10, Maintains Equal-Weight Rating MT
Transcript : Editas Medicine, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Editas Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Editas Medicine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Editas Medicine, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM
RBC Boosts Price Target on Editas Medicine to $11 From $8, Keeps Sector Perform Rating MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals -- Update DJ
Editas Medicine Enters Licensing Deal With Vertex Pharmaceuticals for Cas9 MT
Editas Medicine Strikes License Deal With Vertex Pharmaceuticals DJ
Editas Medicine and Vertex Pharmaceuticals Enter into Non-Exclusive License Agreement for Cas9 CI
Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating MT
Editas Medicine, Inc. Announces New EDIT-301 Safety And Efficacy Data In 17 Patients, Presented At The American Society Of Hematology Annual Meeting And In A Company-Sponsored Webinar CI
Transcript : Editas Medicine, Inc. - Special Call
More news
1 day-0.27%
1 week-5.24%
Current month-26.24%
1 month-32.97%
3 months-28.31%
6 months+7.23%
Current year-26.75%
More quotes
1 week
7.19
Extreme 7.185
7.60
1 month
7.19
Extreme 7.185
11.06
Current year
6.88
Extreme 6.88
11.58
1 year
6.08
Extreme 6.0799
11.91
3 years
6.08
Extreme 6.0799
73.03
5 years
6.08
Extreme 6.0799
99.95
10 years
6.08
Extreme 6.0799
99.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 22-05-31
Director of Finance/CFO 57 23-05-16
Chief Tech/Sci/R&D Officer - 23-07-23
Members of the board TitleAgeSince
Chairman 63 21-09-02
Director/Board Member 71 19-02-05
Director/Board Member 61 16-07-27
More insiders
Date Price Change Volume
24-03-28 7.42 -0.27% 1,561,233
24-03-27 7.44 +3.05% 1,281,507
24-03-26 7.22 -1.90% 1,850,850
24-03-25 7.36 -1.47% 1,171,132
24-03-22 7.47 -4.60% 1,267,855

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
7.42 USD
Average target price
15.4 USD
Spread / Average Target
+107.55%
Consensus
  1. Stock
  2. Equities
  3. Stock Editas Medicine, Inc. - Nasdaq